BioMarin off after earnings, guidance

BioMarin (NASDAQ:BMRN) fell $5.65 (32%) to $12.04 on Thursday after reporting 4Q08 and FY08 earnings that missed the Street's estimates and 2009 revenue guidance that also came in below analysts' expectations. The metabolic, cardiovascular and hematology company posted fourth quarter GAAP diluted EPS of $0.21, missing the Street's estimate of $0.26 but up from $0.03 in 4Q07. Revenues increased 121% to $99 million from $45 million in the prior year's quarter. The Street was expecting $106.1 million. ...